GlassScriptPhysician profile
Steffanie Mccombs
NPI 1841960507
$2,886.97
in general payments reported to CMS, 2019-2025
21 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.96 · 2022: $564 · 2023: $768 · 2024: $734 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $483.86 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $468.00 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $373.39 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.73 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $168.92 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $147.43 | 2022-2025 | Veozah |
| Amgen INC. | $134.04 | 2022-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $131.76 | 2022-2025 | |
| Glaxosmithkline, LLC. | $129.68 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $97.97 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $84.93 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $75.18 | 2022-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Idorsia Pharmaceuticals US INC | $62.63 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $45.59 | 2022 | |
| Phathom Pharmaceuticals, INC. | $41.35 | 2024-2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.28 | 2022 | |
| Medtronic, INC. | $29.20 | 2022-2024 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $16.32 | 2023 | Trintellix |
| Cranial Technologies, INC | $13.69 | 2024 | Doc Band |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steffanie Mccombs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.